Insulet Corp. (PODD) had a quarter that most companies would love, but Wall Street is focused on what's next. The insulin pump maker beat second-quarter expectations, yet its stock took a beating Wednesday after management trimmed the full-year outlook and issued third-quarter guidance that missed the mark.
Here's the numbers breakdown: Adjusted earnings came in at $1.66 per share, up from $1.17 a year ago and ahead of the $1.45 analysts were looking for. Revenue jumped 23.5% to $801.7 million, topping the $787.2 million consensus. Net income climbed to $95 million, or $1.37 per diluted share, compared to $22.5 million, or 32 cents per share, in the same period last year.
Omnipod Keeps Crushing It
The star of the show remains Omnipod. Total Omnipod revenue rose 24.6% to $795.9 million, with U.S. sales up 20.1% to $544.1 million and international revenue surging 35.5% to $251.8 million. Drug Delivery revenue, however, fell to $5.8 million from $10.2 million.
Operating income increased to $129.7 million from $121.1 million, though the operating margin narrowed to 16.2% from 18.7%. Adjusted operating income hit $154.5 million, representing 19.3% of revenue.
During the quarter, Insulet expanded Omnipod 5 into Spain, its 20th country, launched a next-generation algorithm for its automated insulin delivery system, and presented new data on its Omnipod 6 and fully closed-loop technology at the American Diabetes Association's 2026 Scientific Sessions.
CEO Ashley McEvoy struck a confident tone: "We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow." She noted the company is updating its outlook based on what it's learning as it expands in the Type 2 diabetes market, but the long-term growth opportunity remains unchanged.
Cash and cash equivalents stood at $534.9 million at quarter's end, down from $716.1 million at the start of the year. The company generated $202.2 million in operating cash flow in the first half of 2026 and reported free cash flow of $145.4 million.
Guidance Cut Spooks Investors
Here's where things get tricky. For the third quarter, Insulet expects revenue of approximately $829.9 million to $844.0 million, below the $845.5 million analysts had penciled in.
For the full year 2026, the company lowered its revenue outlook to $3.25 billion to $3.30 billion, down from its prior forecast of $3.28 billion to $3.33 billion. That revised range also falls short of the Street's $3.32 billion estimate.
On the earnings front, Insulet expects adjusted EPS to exceed $6.46, which is above the $6.43 analysts were expecting. So it's a mixed bag: better profits, but softer sales growth ahead.
Market Reaction
Investors didn't wait to vote. PODD shares were down 12.13% at $146.58 during premarket trading Wednesday, according to market data.
The selloff highlights how sensitive the market is to guidance, even when a company beats on the headline numbers. For Insulet, the question now is whether the Type 2 diabetes expansion will deliver the growth that justifies the premium valuation.
